Ubs Asset Management Americas Inc Sigilon Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$9.15 - $20.17 $1.13 Million - $2.49 Million	-123,374 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$18.76 - $40.91 $30,503 - $66,519	-1,626 Reduced 1.3%	123,374 $2.76 Million
Q4 2020 Mar 01, 2021	BUY	$27.6 - $48.03 $3.45 Million - $6 Million	125,000 New	125,000 $6 Million

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.